{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:15:21Z","timestamp":1791281721030,"version":"4.1.0"},"reference-count":200,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1016\/j.pharmthera.2009.01.003","type":"journal-article","created":{"date-parts":[[2009,2,9]],"date-time":"2009-02-09T04:12:47Z","timestamp":1234152767000},"page":"65-77","source":"Crossref","is-referenced-by-count":206,"title":["Fabry disease"],"prefix":"10.1016","volume":"122","author":[{"given":"Raphael","family":"Schiffmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.pharmthera.2009.01.003_bib1","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Suppl 2","key":"10.1016\/j.pharmthera.2009.01.003_bib2","doi-asserted-by":"crossref","first-page":"S134","DOI":"10.1097\/01.ASN.0000016684.07368.75","article-title":"Renal pathology in Fabry disease","volume":"13","author":"Alroy","year":"2002","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"10.1016\/j.pharmthera.2009.01.003_bib3","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1161\/01.STR.32.7.1559","article-title":"Enhanced endothelium-dependent vasodilation in Fabry disease","volume":"32","author":"Altarescu","year":"2001","journal-title":"Stroke"},{"issue":"12","key":"10.1016\/j.pharmthera.2009.01.003_bib4","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1212\/01.WNL.0000166000.24321.4F","article-title":"Effect of genetic modifiers on cerebral lesions in Fabry disease","volume":"64","author":"Altarescu","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2009.01.003_bib5","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1365-2133.1898.tb16317.x","article-title":"A case of angiokeratoma","volume":"18","author":"Anderson","year":"1898","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.01.003_bib6","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2215\/CJN.02490607","article-title":"Screening for Fabry disease in patients with chronic kidney disease: Limitations of plasma alpha-galactosidase assay as a screening test","volume":"3","author":"Andrade","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.01.003_bib7","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00428-007-0468-6","article-title":"Cellular and tissue localization of globotriaosylceramide in Fabry disease","volume":"451","author":"Askari","year":"2007","journal-title":"Virchows Arch"},{"key":"10.1016\/j.pharmthera.2009.01.003_bib8","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1600-0404.1999.tb07386.x","article-title":"Mechanisms of pain in peripheral neuropathy","volume":"173","author":"Attal","year":"1999","journal-title":"Acta Neurol Scand Suppl"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.01.003_bib9","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ymgme.2007.10.001","article-title":"Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease","volume":"93","author":"Auray-Blais","year":"2008","journal-title":"Mol Genet Metab"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.01.003_bib10","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1067\/moe.2001.114833","article-title":"Oral and craniofacial findings in Fabry's disease: a report of 13 patients","volume":"92","author":"Baccaglini","year":"2001","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endo"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.01.003_bib11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: a randomized trial","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.01.003_bib12","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1159\/000166730","article-title":"Silicon nephropathy mimicking Fabry's disease","volume":"3","author":"Banks","year":"1983","journal-title":"Am J Nephrol"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.01.003_bib13","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.ATV.0000209649.60409.38","article-title":"Cardiac and vascular hypertrophy in Fabry disease: evidence for a new mechanism independent of blood pressure and glycosphingolipid deposition","volume":"26","author":"Barbey","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"10","key":"10.1016\/j.pharmthera.2009.01.003_bib14","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.amjcard.2005.11.087","article-title":"Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy","volume":"97","author":"Beer","year":"2006","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.01.003_bib15","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1399-0004.1989.tb03367.x","article-title":"Angiokeratoma corporis diffusum in GM1 gangliosidosis, type 1","volume":"36","author":"Beratis","year":"1989","journal-title":"Clin Genet"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.01.003_bib16","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.semnephrol.2008.03.005","article-title":"Vasopressin receptor mutations in nephrogenic diabetes insipidus","volume":"28","author":"Bichet","year":"2008","journal-title":"Semin Nephrol"},{"issue":"11","key":"10.1016\/j.pharmthera.2009.01.003_bib17","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1073\/pnas.85.11.3903","article-title":"Structural organization of the human alpha-galactosidase A gene: further evidence for the absence of a 3' untranslated region","volume":"85","author":"Bishop","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.01.003_bib18","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1161\/01.CIR.0000154550.15963.80","article-title":"Alpha-galactosidase A deficiency accelerates atherosclerosis in mice with apolipoprotein E deficiency","volume":"111","author":"Bodary","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2009.01.003_bib19","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","article-title":"Enzymatic defect in Fabry disease: ceramide trihexosidase deficiency","volume":"276","author":"Brady","year":"1967","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.pharmthera.2009.01.003_bib20","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1001\/jama.284.21.2771","article-title":"Clinical features of and recent advances in therapy for Fabry disease","volume":"284","author":"Brady","year":"2000","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.01.003_bib21","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00005792-200203000-00003","article-title":"Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course","volume":"81","author":"Branton","year":"2002","journal-title":"Medicine (Baltimore)"},{"issue":"11","key":"10.1016\/j.pharmthera.2009.01.003_bib22","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1136\/jnnp.2008.143693","article-title":"Central nervous system involvement in Anderson\u2013Fabry disease: a clinical and MRI retrospective study","volume":"79","author":"Buechner","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.01.003_bib23","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1007\/s00415-008-0786-x","article-title":"The pulvinar sign: frequency and clinical correlations in Fabry disease","volume":"255","author":"Burlina","year":"2008","journal-title":"J Neurol"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.01.003_bib24","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1212\/WNL.32.5.498","article-title":"Fabry disease: impaired autonomic function","volume":"32","author":"Cable","year":"1982","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.pharmthera.2009.01.003_bib25","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1212\/WNL.32.10.1139","article-title":"Fabry disease: detection of heterozygotes by examination of glycolipids in urinary sediment","volume":"32","author":"Cable","year":"1982","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.01.003_bib26","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/archderm.131.1.57","article-title":"Angiokeratoma corporis diffusum and arteriovenous fistulas with dominant transmission in the absence of metabolic disorders","volume":"131","author":"Calzavara-Pinton","year":"1995","journal-title":"Arch Dermatol"},{"issue":"24","key":"10.1016\/j.pharmthera.2009.01.003_bib27","first-page":"1607","volume":"310","author":"Case 2-1984: Fabry's disease","year":"1984","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.01.003_bib28","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1007\/BF00712015","article-title":"Mild phenotypic expression of alpha-N-acetylgalactosaminidase deficiency in two adult siblings","volume":"17","author":"Chabas","year":"1994","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.01.003_bib29","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/ajcp\/82.1.24","article-title":"Immunohistochemical localization of glycosphingolipid in urinary renal tubular cells in Fabry's disease","volume":"82","author":"Chatterjee","year":"1984","journal-title":"Am J Clin Pathol"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.01.003_bib30","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1139\/o84-054","article-title":"Glycosphingolipids and plasma lipoproteins: a review","volume":"62","author":"Chatterjee","year":"1984","journal-title":"Can J Biochem Cell Biol"},{"issue":"8","key":"10.1016\/j.pharmthera.2009.01.003_bib31","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1086\/507705","article-title":"Fabry disease in mice protects against lethal disease caused by Shiga toxin-expressing enterohemorrhagic Escherichia coli","volume":"194","author":"Cilmi","year":"2006","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.01.003_bib32","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0005-2760(76)90152-1","article-title":"Neutral glycosphingolipids of serum lipoproteins in Fabry's disease","volume":"431","author":"Clarke","year":"1976","journal-title":"Biochim Biophys Acta"},{"issue":"443","key":"10.1016\/j.pharmthera.2009.01.003_bib33","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1651-2227.2003.tb00219.x","article-title":"Auditory and vestibular findings in Fabry disease: a study of hemizygous males and heterozygous females","volume":"92","author":"Conti","year":"2003","journal-title":"Acta Paediatr Suppl"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2009.01.003_bib34","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/BF00139581","article-title":"Drug-induced lipidoses of the cornea and conjunctiva","volume":"4","author":"D'Amico","year":"1981","journal-title":"Int Ophthalmol"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.01.003_bib35","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/1531-8249(200002)47:2<229::AID-ANA13>3.0.CO;2-T","article-title":"Profile of endothelial and leukocyte activation in Fabry patients","volume":"47","author":"DeGraba","year":"2000","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2009.01.003_bib36","series-title":"The metabolic and molecular bases of inherited disease","first-page":"3733","article-title":"a-galactosidase A deficiency: Fabry disease","author":"Desnick","year":"2001"},{"key":"10.1016\/j.pharmthera.2009.01.003_bib37","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00109-005-0656-2","article-title":"Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the alpha-galactosidase A gene in the Czech and Slovak population","volume":"83","author":"Dobrovolny","year":"2005","journal-title":"J Mol Med"},{"issue":"451","key":"10.1016\/j.pharmthera.2009.01.003_bib38","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/08035320600618759","article-title":"The pattern of inheritance of X-linked traits is not dominant or recessive, just X-linked","volume":"95","author":"Dobyns","year":"2006","journal-title":"Acta Paediatr Suppl"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.01.003_bib39","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1159\/000184389","article-title":"Natural history and treatment of uremia secondary to Fabry's disease: an European experience","volume":"46","author":"Donati","year":"1987","journal-title":"Nephron"},{"issue":"8","key":"10.1016\/j.pharmthera.2009.01.003_bib40","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/ncpendmet0894","article-title":"The pathogenesis of diabetic nephropathy","volume":"4","author":"Dronavalli","year":"2008","journal-title":"Nat Clin Pract Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.01.003_bib41","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3109\/00313027009077320","article-title":"The renal lesion of angiokeratoma corporis diffusum (Fabry's disease): report of three cases including some electron microscopic findings","volume":"2","author":"Duncan","year":"1970","journal-title":"Pathology"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.01.003_bib42","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/00004691-200212000-00011","article-title":"Small fiber dysfunction predominates in Fabry neuropathy","volume":"19","author":"Dutsch","year":"2002","journal-title":"J Clin Neurophysiol"},{"issue":"443","key":"10.1016\/j.pharmthera.2009.01.003_bib43","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1651-2227.2003.tb00222.x","article-title":"Sequelae of storage in Fabry disease\u2014pathology and comparison with other lysosomal storage diseases","volume":"92","author":"Elleder","year":"2003","journal-title":"Acta Paediatr Suppl"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.01.003_bib44","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s00428-008-0614-9","article-title":"Cellular and tissue localization of globotriaosylceramide in Fabry disease","volume":"452","author":"Elleder","year":"2008","journal-title":"Virchows Arch"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.01.003_bib45","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1086\/318809","article-title":"A phase 1\/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies","volume":"68","author":"Eng","year":"2001","journal-title":"Am J Hum Genet"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.01.003_bib46","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s10545-007-0521-2","article-title":"Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry","volume":"30","author":"Eng","year":"2007","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.01.003_bib47","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A\u2014 replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.01.003_bib48","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10545-005-0575-y","article-title":"Enzyme replacement therapy in Japanese Fabry disease patients: The results of a phase 2 bridging study","volume":"28","author":"Eto","year":"2005","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.pharmthera.2009.01.003_bib49","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF01986897","article-title":"Ein Betrag zur Kenntnis der Ppurpura hammarrhagica nodularis","volume":"43","author":"Fabry","year":"1898","journal-title":"Arch Dermatol Syphilol"},{"issue":"11","key":"10.1016\/j.pharmthera.2009.01.003_bib50","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1210\/jc.2006-0858","article-title":"Endocrine dysfunction in patients with Fabry disease","volume":"91","author":"Faggiano","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"19","key":"10.1016\/j.pharmthera.2009.01.003_bib51","doi-asserted-by":"crossref","first-page":"4962","DOI":"10.1111\/j.1742-4658.2007.06041.x","article-title":"Active-site-specific chaperone therapy for Fabry disease. Yin and Yang of enzyme inhibitors","volume":"274","author":"Fan","year":"2007","journal-title":"Febs J"},{"issue":"9","key":"10.1016\/j.pharmthera.2009.01.003_bib52","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nm.1857","article-title":"The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A","volume":"14","author":"Faul","year":"2008","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.01.003_bib53","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1365-2230.1997.tb01064.x","article-title":"Idiopathic angiokeratoma corporis diffusum","volume":"22","author":"Fimiani","year":"1997","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.01.003_bib54","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/ncpcardio1211","article-title":"Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies","volume":"5","author":"Forstermann","year":"2008","journal-title":"Nat Clin Pract Cardiovasc Med"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.01.003_bib55","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1373\/clinchem.2004.041418","article-title":"Urinary lipid profiling for the identification of fabry hemizygotes and heterozygotes","volume":"51","author":"Fuller","year":"2005","journal-title":"Clin Chem"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.01.003_bib56","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/jmg.20.4.309","article-title":"Involvement of dorsal root ganglia in Fabry's disease","volume":"20","author":"Gadoth","year":"1983","journal-title":"J Med Genet"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.01.003_bib57","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jmb.2004.01.035","article-title":"The molecular defect leading to Fabry disease: structure of human alpha-galactosidase","volume":"337","author":"Garman","year":"2004","journal-title":"J Mol Biol"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.01.003_bib58","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1365-2230.1992.tb02537.x","article-title":"Angiokeratoma corporis diffusum in a patient with normal enzyme activities and Turner's syndrome","volume":"17","author":"Gasparini","year":"1992","journal-title":"Clin Exp Dermatol"},{"issue":"7","key":"10.1016\/j.pharmthera.2009.01.003_bib59","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1161\/ATVBAHA.107.143511","article-title":"Elevated endothelial microparticles in Fabry children decreased after enzyme replacement therapy","volume":"27","author":"Gelderman","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"11","key":"10.1016\/j.pharmthera.2009.01.003_bib60","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1177\/014107689408701124","article-title":"Angiokeratoma corporis diffusum in fucosidosis","volume":"87","author":"George","year":"1994","journal-title":"J R Soc Med"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.01.003_bib61","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease","volume":"18","author":"Germain","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.01.003_bib62","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/00004728-200403000-00002","article-title":"Fabry disease: renal sonographic and magnetic resonance imaging findings in affected males and carrier females with the classic and cardiac variant phenotypes","volume":"28","author":"Glass","year":"2004","journal-title":"J Comput Assist Tomogr"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.01.003_bib63","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/0887-8994(95)00007-3","article-title":"Successful treatment of painful crises of Fabry disease with low dose morphine","volume":"12","author":"Gordon","year":"1995","journal-title":"Pediatr Neurol"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.01.003_bib64","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.ncl.2008.07.003","article-title":"Epidemiology of ischemic and hemorrhagic stroke: incidence, prevalence, mortality, and risk factors","volume":"26","author":"Grysiewicz","year":"2008","journal-title":"Neurol Clin"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.01.003_bib65","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1023\/B:BOLI.0000028726.11177.8b","article-title":"Clinical benefit in Fabry patients given enzyme replacement therapy\u2014a case series","volume":"27","author":"Guffon","year":"2004","journal-title":"J Inherit Metab Dis"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.01.003_bib66","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/01.md.0000178976.62537.6b","article-title":"The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women","volume":"84","author":"Gupta","year":"2005","journal-title":"Medicine (Baltimore)"},{"issue":"8","key":"10.1016\/j.pharmthera.2009.01.003_bib67","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1023\/B:BOLI.0000009948.86528.72","article-title":"Hearing loss in Fabry disease: the effect of agalsidase alfa replacement therapy","volume":"26","author":"Hajioff","year":"2003","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.pharmthera.2009.01.003_bib68","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/jid.1965.22","article-title":"Angiokeratoma corporis diffusum (Fabry). Histochemical and electron microscopic studies of the skin","volume":"44","author":"Hashimoto","year":"1965","journal-title":"J Invest Dermatol"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.01.003_bib69","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s10545-005-0003-3","article-title":"High prevalence of subclinical hypothyroidism in patients with Anderson\u2013Fabry disease","volume":"28","author":"Hauser","year":"2005","journal-title":"J Inherit Metab Dis"},{"issue":"7","key":"10.1016\/j.pharmthera.2009.01.003_bib70","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1212\/01.WNL.0000118207.84514.40","article-title":"Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy","volume":"62","author":"Hilz","year":"2004","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.01.003_bib71","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1007\/s00415-004-0364-9","article-title":"Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease","volume":"251","author":"Hilz","year":"2004","journal-title":"J Neurol"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.01.003_bib72","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1136\/jmg.2004.025791","article-title":"Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey)","volume":"42","author":"Hoffmann","year":"2005","journal-title":"J Med Genet"},{"issue":"455","key":"10.1016\/j.pharmthera.2009.01.003_bib73","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1651-2227.2007.00216.x","article-title":"Gastrointestinal symptoms in Fabry disease: everything is possible, including treatment","volume":"96","author":"Hoffmann","year":"2007","journal-title":"Acta Paediatr Suppl"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.01.003_bib74","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1203\/PDR.0b013e318183f132","article-title":"Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry","volume":"64","author":"Hopkin","year":"2008","journal-title":"Pediatr Res"},{"issue":"3\u20134","key":"10.1016\/j.pharmthera.2009.01.003_bib75","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/BF01478472","article-title":"[Excision of skin in diagnosis of Fabry's angiokeratoma with cardio-vasorenal syndrome as phosphatide storage disease.]","volume":"31","author":"Hornbostel","year":"1953","journal-title":"Klin Wochenschr"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.01.003_bib76","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.mcna.2006.10.002","article-title":"The diagnostic workup of patients with neuropathic pain","volume":"91","author":"Horowitz","year":"2007","journal-title":"Med Clin North Am"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.01.003_bib77","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/hrt.2006.104026","article-title":"Effects of enzyme replacement therapy on the cardiomyopathy of Anderson\u2013Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa","volume":"94","author":"Hughes","year":"2008","journal-title":"Heart"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.01.003_bib78","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/BF00227722","article-title":"Lysosomal glycosphingolipid storage in chloroquine-induced alpha-galactosidase-deficient human endothelial cells with transformation by simian virus 40: in vitro model of Fabry disease","volume":"85","author":"Inagaki","year":"1993","journal-title":"Acta Neuropathol"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.01.003_bib79","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.bbrc.2007.02.053","article-title":"Dynamic interplay between the neutral glycosphingolipid CD77\/Gb3 and the therapeutic antibody target CD20 within the lipid bilayer of model B lymphoma cells","volume":"355","author":"Jarvis","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.01.003_bib80","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s10545-005-0563-2","article-title":"Impaired myocardial perfusion reserve but preserved peripheral endothelial function in patients with Fabry disease","volume":"28","author":"Kalliokoski","year":"2005","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.01.003_bib81","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s10545-006-0221-3","article-title":"The effect of 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease","volume":"29","author":"Kalliokoski","year":"2006","journal-title":"J Inherit Metab Dis"},{"issue":"447","key":"10.1016\/j.pharmthera.2009.01.003_bib82","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/08035320510028049","article-title":"The right ventricle in Fabry disease","volume":"94","author":"Kampmann","year":"2005","journal-title":"Acta Paediatr Suppl"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.01.003_bib83","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijcard.2008.03.007","article-title":"Onset and progression of the Anderson\u2013Fabry disease related cardiomyopathy","volume":"130","author":"Kampmann","year":"2008","journal-title":"Int J Cardiol"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.01.003_bib84","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1651-2227.2008.00700.x","article-title":"Cardiac manifestations of Anderson\u2013Fabry disease in children and adolescents","volume":"97","author":"Kampmann","year":"2008","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.pharmthera.2009.01.003_bib85","doi-asserted-by":"crossref","unstructured":"Kaneski, C. R., Moore, D. F., Ries, M., Zirzow, R., Schiffmann, R. (2006). Myeloperoxidase predicts risk for vasculopathic events in Fabry disease. Neurology 67, 2045\u20132047.","DOI":"10.1212\/01.wnl.0000247278.88077.09"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.01.003_bib86","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1159\/000017956","article-title":"Angiokeratoma corporis diffusum associated with galactosialidosis","volume":"197","author":"Kawachi","year":"1998","journal-title":"Dermatology"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.01.003_bib87","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.amjcard.2006.07.088","article-title":"Significance of asymmetric basal posterior wall thinning in patients with cardiac Fabry's disease","volume":"99","author":"Kawano","year":"2007","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.01.003_bib88","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/ana.410230513","article-title":"Nervous system involvement in Fabry's disease: clinicopathological and biochemical correlation","volume":"23","author":"Kaye","year":"1988","journal-title":"Ann Neurol"},{"issue":"443","key":"10.1016\/j.pharmthera.2009.01.003_bib89","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1651-2227.2003.tb00218.x","article-title":"Inner ear function in children with Fabry disease","volume":"92","author":"Keilmann","year":"2003","journal-title":"Acta Paediatr Suppl"},{"issue":"922","key":"10.1016\/j.pharmthera.2009.01.003_bib90","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1126\/science.167.3922.1268","article-title":"Fabry's disease: alpha-galactosidase deficiency","volume":"167","author":"Kint","year":"1970","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.pharmthera.2009.01.003_bib91","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1007\/s00467-008-0846-6","article-title":"Non-invasive high-risk screening for Fabry disease hemizygotes and heterozygotes","volume":"23","author":"Kitagawa","year":"2008","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.01.003_bib92","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1111\/j.1523-1755.2005.00294.x","article-title":"Anemia is a new complication in Fabry disease: data from the Fabry Outcome Survey","volume":"67","author":"Kleinert","year":"2005","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.01.003_bib93","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1046\/j.1365-2133.2001.04028.x","article-title":"A new case of alpha-N-acetylgalactosaminidase deficiency with angiokeratoma corporis diffusum, with Meniere's syndrome and without mental retardation","volume":"144","author":"Kodama","year":"2001","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.01.003_bib94","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.clinph.2008.02.004","article-title":"Neuropathic symptoms and findings in women with Fabry disease","volume":"119","author":"Laaksonen","year":"2008","journal-title":"Clin Neurophysiol"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.01.003_bib95","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/mus.20130","article-title":"Neuropathy and Fabry's disease","volume":"31","author":"Lacomis","year":"2005","journal-title":"Muscle Nerve"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.01.003_bib96","first-page":"341","article-title":"Interpretation of pure-tone thresholds in sensorineural hearing loss (SNHL): a review of measurement variability and age-specific references","volume":"56","author":"Lemkens","year":"2002","journal-title":"Acta Otorhinolaryngol Belg"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.01.003_bib97","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1067\/mhj.2000.105105","article-title":"New insights in cardiac structural changes in patients with Fabry's disease","volume":"139","author":"Linhart","year":"2000","journal-title":"Am Heart J"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.01.003_bib98","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1445-5994.2008.01669.x","article-title":"Cardiovascular testing in Fabry disease: exercise capacity reduction, chronotropic incompetence and improved anaerobic threshold after enzyme replacement","volume":"38","author":"Lobo","year":"2008","journal-title":"Intern Med J"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.01.003_bib99","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/1086508X.1999.11079251","article-title":"The autonomic laboratory","volume":"39","author":"Low","year":"1999","journal-title":"Am J Electroneurodiagn Technol"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.01.003_bib100","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0950-821X(88)80062-8","article-title":"An unusual cause of lymphoedema\u2014confirmed by isotopic lymphangiography","volume":"2","author":"Lozano","year":"1988","journal-title":"Eur J Vasc Surg"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.01.003_bib101","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/mus.10236","article-title":"Physiologic characterization of neuropathy in Fabry disease","volume":"26","author":"Luciano","year":"2002","journal-title":"Muscle Nerve"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.01.003_bib102","doi-asserted-by":"crossref","first-page":"E12","DOI":"10.1136\/jmg.38.4.e12","article-title":"New problems in testing for Huntington's disease: the issue of intermediate and reduced penetrance alleles","volume":"38","author":"Maat-Kievit","year":"2001","journal-title":"J Med Genet"},{"issue":"1\u20133","key":"10.1016\/j.pharmthera.2009.01.003_bib103","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0014-2999(01)01312-7","article-title":"Neuropathic pain in Anderson\u2013Fabry disease: pathology and therapeutic options","volume":"429","author":"MacDermot","year":"2001","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.01.003_bib104","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3109\/13816818509006132","article-title":"Corneal changes in Fabry's disease: a clinico-pathologic case report of a heterozygote","volume":"5","author":"Macrae","year":"1985","journal-title":"Ophthalmic Paediatr Genet"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.01.003_bib105","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1440-0960.2007.00326.x","article-title":"Fabry disease in a heterozygote presenting as hand ischaemia and painful acroparaesthesia","volume":"48","author":"Martin","year":"2007","journal-title":"Australas J Dermatol"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2009.01.003_bib106","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ymgme.2008.07.002","article-title":"Enzyme replacement therapy in Fabry disease: comparison of agalsidase alfa and agalsidase beta","volume":"95","author":"Mehta","year":"2008","journal-title":"Mol Genet Metab"},{"issue":"447","key":"10.1016\/j.pharmthera.2009.01.003_bib107","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1080\/08035320510028076","article-title":"Natural history of the cerebrovascular complications of Fabry disease","volume":"94","author":"Mehta","year":"2005","journal-title":"Acta Paediatr Suppl"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.01.003_bib108","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur J Clin Invest"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.01.003_bib109","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.01.003_bib110","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/hep.1840020214","article-title":"Ultrastructural and biochemical liver analyses in Fabry's disease","volume":"2","author":"Meuwissen","year":"1982","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.01.003_bib111","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ana.410400105","article-title":"Cerebrovascular complications of Fabry's disease","volume":"40","author":"Mitsias","year":"1996","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.01.003_bib112","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.brainresbull.2003.09.021","article-title":"White matter lesions in Fabry disease occur in \u2018prior\u2019 selectively hypometabolic and hyperperfused brain regions","volume":"62","author":"Moore","year":"2003","journal-title":"Brain Res Bull"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.01.003_bib113","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2377-2-4","article-title":"Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease","volume":"2","author":"Moore","year":"2002","journal-title":"BMC Neurol"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.01.003_bib114","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1161\/hs0202.102601","article-title":"Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement","volume":"33","author":"Moore","year":"2002","journal-title":"Stroke"},{"issue":"19","key":"10.1016\/j.pharmthera.2009.01.003_bib115","doi-asserted-by":"crossref","first-page":"8065","DOI":"10.1073\/pnas.0701991104","article-title":"Genomic abnormalities of the murine model of Fabry disease after disease-related perturbation, a systems biology approach","volume":"104","author":"Moore","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.01.003_bib116","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1552-6569.2001.tb00051.x","article-title":"Selective arterial distribution of cerebral hyperperfusion in Fabry disease","volume":"11","author":"Moore","year":"2001","journal-title":"J Neuroimaging"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2009.01.003_bib117","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jns.2007.01.053","article-title":"The cerebral vasculopathy of Fabry disease","volume":"257","author":"Moore","year":"2007","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.pharmthera.2009.01.003_bib200","doi-asserted-by":"crossref","unstructured":"Moore, D. F., Krokhin, O. V., Beavis, R. C., Ries, M., Robinson, C., Goldin, E., et al. (2007). Proteomics of disease-related perturbations in Fabry disease: A strategy to identify biological abnormalities. Proc Natl Acad Sci U S A 104, 2873\u20132878.","DOI":"10.1073\/pnas.0611315104"},{"issue":"13","key":"10.1016\/j.pharmthera.2009.01.003_bib118","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1161\/hc3801.096352","article-title":"Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy","volume":"104","author":"Moore","year":"2001","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.01.003_bib119","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/jmri.20162","article-title":"Ascorbate decreases Fabry cerebral hyperperfusion suggesting a reactive oxygen species abnormality: an arterial spin tagging study","volume":"20","author":"Moore","year":"2004","journal-title":"J Magn Reson Imaging"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.01.003_bib120","first-page":"1096","article-title":"Increased signal intensity in the pulvinar on T1-weighted images: a pathognomonic MR imaging sign of Fabry disease","volume":"24","author":"Moore","year":"2003","journal-title":"AJNR Am J Neuroradiol"},{"issue":"18","key":"10.1016\/j.pharmthera.2009.01.003_bib121","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMoa075463","article-title":"Shared genetic causes of cardiac hypertrophy in children and adults","volume":"358","author":"Morita","year":"2008","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.01.003_bib122","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00228-007-0460-8","article-title":"Fabry disease and treatment with agalsidase alpha: unsuspected cardiac arrhythmia in two heterozygous women. In reference to pharmacovigilance","volume":"64","author":"Mougenot","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.01.003_bib123","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ymgme.2006.11.008","article-title":"Cellular and tissue distribution of intravenously administered agalsidase alfa","volume":"90","author":"Murray","year":"2007","journal-title":"Mol Genet Metab"},{"issue":"7","key":"10.1016\/j.pharmthera.2009.01.003_bib124","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1111\/j.1540-8159.1999.tb00584.x","article-title":"Dynamic left ventricular arterial pressure gradient and sick sinus syndrome with heterozygous Fabry's disease improved following implantation of a dual chamber pacemaker","volume":"22","author":"Nakayama","year":"1999","journal-title":"Pacing Clin Electrophysiol"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.01.003_bib125","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/path.1711410203","article-title":"Testicular and epididymal involvement in Fabry's disease","volume":"141","author":"Nistal","year":"1983","journal-title":"J Pathol"},{"issue":"11","key":"10.1016\/j.pharmthera.2009.01.003_bib126","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1097\/00007890-200006150-00020","article-title":"Excellent outcome of renal transplantation in patients with Fabry's disease","volume":"69","author":"Ojo","year":"2000","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.01.003_bib127","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/j.1440-1789.2008.00883.x","article-title":"An autopsy case of Fabry disease with neuropathological investigation of the pathogenesis of associated dementia","volume":"28","author":"Okeda","year":"2008","journal-title":"Neuropathology"},{"key":"10.1016\/j.pharmthera.2009.01.003_bib128","first-page":"325","article-title":"The genetics of angiokeratoma corporis diffusum (Fabry's disease), and its linkage with Xg(a) locus","volume":"17","author":"Opitz","year":"1965","journal-title":"Am J Hum Genet"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.01.003_bib129","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1093\/ndt\/gfm848","article-title":"Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy","volume":"23","author":"Ortiz","year":"2008","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"10.1016\/j.pharmthera.2009.01.003_bib130","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/j.1440-1681.2008.04984.x","article-title":"Vascular dysfunction in the alpha-galactosidase A-knockout mouse is an endothelial cell-, plasma membrane-based defect","volume":"35","author":"Park","year":"2008","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.01.003_bib131","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.0954-6820.1947.tb06596.x","article-title":"Angiokeratoma corporis diffusum (universale) Fabry, as a sign of an unknown internal disease; two autopsy reports","volume":"128","author":"Pompen","year":"1947","journal-title":"Acta Med Scand"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.01.003_bib132","first-page":"295","article-title":"Non invasive evaluation of endothelial function in patients with Anderson\u2013Fabry disease","volume":"24","author":"Puccio","year":"2005","journal-title":"Int Angiol"},{"issue":"457","key":"10.1016\/j.pharmthera.2009.01.003_bib133","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1651-2227.2008.00658.x","article-title":"Fabry disease during childhood: clinical manifestations and treatment with agalsidase alfa","volume":"97","author":"Ramaswami","year":"2008","journal-title":"Acta Paediatr Suppl"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.01.003_bib134","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/08035250500275022","article-title":"Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey","volume":"95","author":"Ramaswami","year":"2006","journal-title":"Acta Paediatr"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.01.003_bib135","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/j.1523-1755.2004.00846.x","article-title":"Parapelvic kidney cysts: a distinguishing feature with high prevalence in Fabry disease","volume":"66","author":"Ries","year":"2004","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.01.003_bib136","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1542\/peds.2005-2895","article-title":"Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease","volume":"118","author":"Ries","year":"2006","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.01.003_bib137","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1542\/peds.2004-1678","article-title":"Pediatric Fabry disease","volume":"115","author":"Ries","year":"2005","journal-title":"Pediatrics"},{"issue":"Pt 1","key":"10.1016\/j.pharmthera.2009.01.003_bib138","first-page":"143","article-title":"Neuropathic and cerebrovascular correlates of hearing loss in Fabry disease","volume":"130","author":"Ries","year":"2007","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.01.003_bib139","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1025127723729","article-title":"Use of gabapentin to reduce chronic neuropathic pain in Fabry disease","volume":"26","author":"Ries","year":"2003","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.01.003_bib140","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/01.gim.0000200950.25118.dd","article-title":"Quantitative dysmorphology assessment in Fabry disease","volume":"8","author":"Ries","year":"2006","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.01.003_bib141","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.nbd.2008.09.001","article-title":"Neurophysiological, behavioral and morphological abnormalities in the Fabry knockout mice","volume":"33","author":"Rodrigues","year":"2009","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.pharmthera.2009.01.003_bib142","doi-asserted-by":"crossref","DOI":"10.1007\/s10545-008-0920-z","article-title":"Association between polymorphisms of endothelial nitric oxide synthase gene (NOS3) and left posterior wall thickness (LPWT) of the heart in Fabry disease","author":"Rohard","year":"2008","journal-title":"J Inherit Metab Dis."},{"issue":"9499","key":"10.1016\/j.pharmthera.2009.01.003_bib143","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/S0140-6736(05)67635-0","article-title":"Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study","volume":"366","author":"Rolfs","year":"2005","journal-title":"Lancet"},{"issue":"9\u201310","key":"10.1016\/j.pharmthera.2009.01.003_bib144","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/BF00484919","article-title":"Residual activity of alpha-galactosidase A in Fabry's disease","volume":"13","author":"Romeo","year":"1975","journal-title":"Biochem Genet"},{"issue":"954","key":"10.1016\/j.pharmthera.2009.01.003_bib145","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1126\/science.170.3954.180","article-title":"Genetic inactivation of the alpha-galactosidase locus in carriers of Fabry's disease","volume":"170","author":"Romeo","year":"1970","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.01.003_bib146","doi-asserted-by":"crossref","first-page":"628","DOI":"10.7326\/0003-4819-81-5-628","article-title":"Intestinal manifestations of Fabry's disease","volume":"81","author":"Rowe","year":"1974","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1016\/j.pharmthera.2009.01.003_bib147","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1161\/01.CIR.0000012626.81324.38","article-title":"Prevalence of Anderson\u2013Fabry disease in male patients with late onset hypertrophic cardiomyopathy","volume":"105","author":"Sachdev","year":"2002","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.pharmthera.2009.01.003_bib148","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1161\/CIRCULATIONAHA.107.731679","article-title":"Role of caveolar compartmentation in endothelium-derived hyperpolarizing factor-mediated relaxation: Ca2+ signals and gap junction function are regulated by caveolin in endothelial cells","volume":"117","author":"Saliez","year":"2008","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.01.003_bib149","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1681\/ASN.2006111263","article-title":"Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing","volume":"18","author":"Schiffmann","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2009.01.003_bib150","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/mus.10497","article-title":"Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease","volume":"28","author":"Schiffmann","year":"2003","journal-title":"Muscle Nerve"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.01.003_bib151","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/mus.10497","article-title":"Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease","volume":"28","author":"Schiffmann","year":"2003","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.pharmthera.2009.01.003_bib152","series-title":"Paper presented at the Annual Meeting of the America Society of Human Genetics","article-title":"Phase 2 clinical trials of the pharmacological chaperone AT1001 for the treatment of Fabry disease","author":"Schiffmann","year":"2008"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.01.003_bib153","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/mus.20550","article-title":"Enzyme replacement therapy and intraepidermal innervation density in Fabry disease","volume":"34","author":"Schiffmann","year":"2006","journal-title":"Muscle Nerve"},{"issue":"21","key":"10.1016\/j.pharmthera.2009.01.003_bib154","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2009.01.003_bib155","first-page":"1","article-title":"Pathological findings in a patient with Fabry disease who died after 2.5\u00a0years of enzyme replacement","author":"Schiffmann","year":"2005","journal-title":"Virchows Arch"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.01.003_bib156","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfi152","article-title":"Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting","volume":"21","author":"Schiffmann","year":"2006","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.01.003_bib157","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10719-007-9091-7","article-title":"Glycosphingolipids in vascular endothelial cells: relationship of heterogeneity in Gb3Cer\/CD77 receptor expression with differential Shiga toxin 1 cytotoxicity","volume":"25","author":"Schweppe","year":"2008","journal-title":"Glycoconj J"},{"issue":"8","key":"10.1016\/j.pharmthera.2009.01.003_bib158","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/j.1540-8167.2005.40842.x","article-title":"Genetics of right ventricular cardiomyopathy","volume":"16","author":"Sen-Chowdhry","year":"2005","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.01.003_bib159","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1034\/j.1399-0004.2003.630107.x","article-title":"Fabry disease: a functional and anatomical study of cardiac manifestations in 20 hemizygous male patients","volume":"63","author":"Senechal","year":"2003","journal-title":"Clin Genet"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.01.003_bib160","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1046\/j.1468-1331.2003.00675.x","article-title":"Acetazolamide as a vasodilatory stimulus in cerebrovascular diseases and in conditions affecting the cerebral vasculature","volume":"10","author":"Settakis","year":"2003","journal-title":"Eur J Neurol"},{"issue":"8","key":"10.1016\/j.pharmthera.2009.01.003_bib161","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1172\/JCI32022","article-title":"Proteolytic processing of dynamin by cytoplasmic cathepsin L is a mechanism for proteinuric kidney disease","volume":"117","author":"Sever","year":"2007","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.01.003_bib162","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1161\/01.STR.0000206442.86238.39","article-title":"Alpha-galactosidase A deficiency leads to increased tissue fibrin deposition and thrombosis in mice homozygous for the factor V Leiden mutation","volume":"37","author":"Shen","year":"2006","journal-title":"Stroke"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.01.003_bib163","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ymgme.2008.06.016","article-title":"Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells","volume":"95","author":"Shen","year":"2008","journal-title":"Mol Genet Metab"},{"issue":"29","key":"10.1016\/j.pharmthera.2009.01.003_bib164","doi-asserted-by":"crossref","first-page":"20960","DOI":"10.1074\/jbc.M702436200","article-title":"Caveolin-associated accumulation of globotriaosylceramide in the vascular endothelium of alpha-galactosidase A null mice","volume":"282","author":"Shu","year":"2007","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.01.003_bib165","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1136\/bjo.2006.100602","article-title":"Ocular manifestations of Fabry's disease: data from the Fabry Outcome Survey","volume":"91","author":"Sodi","year":"2007","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.01.003_bib166","doi-asserted-by":"crossref","first-page":"H385","DOI":"10.1152\/ajpheart.01047.2005","article-title":"Evidence for the involvement of myoendothelial gap junctions in EDHF-mediated relaxation in the rat middle cerebral artery","volume":"291","author":"Sokoya","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.01.003_bib167","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset Fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am J Hum Genet"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.01.003_bib168","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1399-0004.2004.00284.x","article-title":"Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease","volume":"66","author":"Spinelli","year":"2004","journal-title":"Clin Genet"},{"issue":"8","key":"10.1016\/j.pharmthera.2009.01.003_bib169","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1007\/s00415-003-1133-x","article-title":"Postischemic cutaneous hyperperfusion in the presence of forearm hypoperfusion suggests sympathetic vasomotor dysfunction in Fabry disease","volume":"250","author":"Stemper","year":"2003","journal-title":"J Neurol"},{"issue":"11","key":"10.1016\/j.pharmthera.2009.01.003_bib170","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/j.1346-8138.2004.tb00630.x","article-title":"Beta-mannosidosis with angiokeratoma corporis diffusum","volume":"31","author":"Suzuki","year":"2004","journal-title":"J Dermatol"},{"key":"10.1016\/j.pharmthera.2009.01.003_bib171","doi-asserted-by":"crossref","first-page":"PC3148","DOI":"10.1016\/S0021-9258(18)51888-3","article-title":"Fabry's disease: classification as a sphingolipidosis and partial characterization of a novel glycolipid","volume":"238","author":"Sweeley","year":"1963","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.01.003_bib172","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/BF00690579","article-title":"Anderson\u2013Fabry's disease: neuropathological and neurochemical investigation","volume":"56","author":"Tagliavini","year":"1982","journal-title":"Acta Neuropathol"},{"issue":"9","key":"10.1016\/j.pharmthera.2009.01.003_bib173","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1681\/ASN.2006121400","article-title":"Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta","volume":"18","author":"Tahir","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"10.1016\/j.pharmthera.2009.01.003_bib174","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1084\/jem.20080106","article-title":"Crucial role of nitric oxide synthases system in endothelium-dependent hyperpolarization in mice","volume":"205","author":"Takaki","year":"2008","journal-title":"J Exp Med"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.01.003_bib175","first-page":"916","article-title":"T1 hyperintensity in the pulvinar: key imaging feature for diagnosis of Fabry disease","volume":"24","author":"Takanashi","year":"2003","journal-title":"AJNR Am J Neuroradiol"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.01.003_bib176","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jjcc.2007.12.001","article-title":"Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study","volume":"51","author":"Takenaka","year":"2008","journal-title":"J Cardiol"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.01.003_bib177","doi-asserted-by":"crossref","first-page":"281","DOI":"10.5414\/CNP64281","article-title":"Identification of Fabry's disease by the screening of alpha-galactosidase A activity in male and female hemodialysis patients","volume":"64","author":"Tanaka","year":"2005","journal-title":"Clin Nephrol"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.01.003_bib178","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1093\/ndt\/gfm532","article-title":"Two-tier approach for the detection of alpha-galactosidase A deficiency in a predominantly female haemodialysis population","volume":"23","author":"Terryn","year":"2008","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.01.003_bib179","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1046\/j.1523-1755.2002.00097.x","article-title":"Patients with Fabry disease on dialysis in the United States","volume":"61","author":"Thadhani","year":"2002","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2009.01.003_bib180","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/ki.2008.576","article-title":"Downregulation of alpha-galactosidase A upregulates CD77: Functional impact for Fabry nephropathy","volume":"75","author":"Thomaidis","year":"2009","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.01.003_bib181","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.2165\/00003495-200060050-00005","article-title":"Anticonvulsants for neuropathic pain syndromes: mechanisms of action and place in therapy","volume":"60","author":"Tremont-Lukats","year":"2000","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.01.003_bib182","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/path.1711010303","article-title":"Fine structure of the skin in angiokeratoma corporis diffusum (Fabry's disease)","volume":"101","author":"van Mullem","year":"1970","journal-title":"J Pathol"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.01.003_bib183","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ymgme.2008.03.003","article-title":"Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3","volume":"94","author":"Vedder","year":"2008","journal-title":"Mol Genet Metab"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.01.003_bib184","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s10545-006-0484-8","article-title":"The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels","volume":"30","author":"Vedder","year":"2007","journal-title":"J Inherit Metab Dis"},{"issue":"15","key":"10.1016\/j.pharmthera.2009.01.003_bib185","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1161\/01.CIR.0000033853.29869.08","article-title":"Prevalence of Anderson\u2013Fabry disease in male patients with late onset hypertrophic cardiomyopathy","volume":"106","author":"Veinot","year":"2002","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.01.003_bib186","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1177\/000348940611500603","article-title":"Fabry's disease: otoneurologic findings in twelve members of one family","volume":"115","author":"Vibert","year":"2006","journal-title":"Ann Otol Rhinol Laryngol"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.01.003_bib187","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/GIM.0b013e31802d8321","article-title":"Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life","volume":"9","author":"Wang","year":"2007","journal-title":"Genet Med"},{"issue":"3 Pt 2","key":"10.1016\/j.pharmthera.2009.01.003_bib188","first-page":"H1262","article-title":"Mechanisms of cerebral vasodilation by superoxide, hydrogen peroxide, and peroxynitrite","volume":"271","author":"Wei","year":"1996","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2009.01.003_bib189","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1055\/s-0028-1136780","article-title":"Angiomatosis, bzw. Angiokeratosis universalis (eine sehr seltene Haut-und Gafasskrankheit)","volume":"51","author":"Weicksel","year":"1925","journal-title":"Dtsch Med Wochenschr"},{"issue":"12","key":"10.1016\/j.pharmthera.2009.01.003_bib190","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/eurheartj\/ehi143","article-title":"The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease","volume":"26","author":"Weidemann","year":"2005","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.pharmthera.2009.01.003_bib191","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1161\/01.CIR.0000091253.71282.04","article-title":"Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study","volume":"108","author":"Weidemann","year":"2003","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.pharmthera.2009.01.003_bib192","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1001\/jama.249.16.2177b","article-title":"Amiodarone phenocopy of Fabry's keratopathy","volume":"249","author":"Whitley","year":"1983","journal-title":"Jama"},{"issue":"7","key":"10.1016\/j.pharmthera.2009.01.003_bib193","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1023\/A:1012993305223","article-title":"Anderson\u2013Fabry disease: clinical manifestations of disease in female heterozygotes","volume":"24","author":"Whybra","year":"2001","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.01.003_bib194","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","article-title":"Long-term safety and efficacy of enzyme replacement therapy for Fabry disease","volume":"75","author":"Wilcox","year":"2004","journal-title":"Am J Hum Genet"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.01.003_bib195","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","article-title":"Females with Fabry disease frequently have major organ involvement: Lessons from the Fabry Registry","volume":"93","author":"Wilcox","year":"2008","journal-title":"Mol Genet Metab"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.01.003_bib196","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jpeds.2007.09.007","article-title":"Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease","volume":"152","author":"Wraith","year":"2008","journal-title":"J Pediatr"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.01.003_bib197","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1346-8138.1995.tb03333.x","article-title":"Histopathologic and ultrastructural studies of angiokeratoma corporis diffusum in Kanzaki disease","volume":"22","author":"Yokota","year":"1995","journal-title":"J Dermatol"},{"issue":"9647","key":"10.1016\/j.pharmthera.2009.01.003_bib198","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(08)61589-5","article-title":"Fabry's disease","volume":"372","author":"Zarate","year":"2008","journal-title":"Lancet"},{"issue":"1\u20133","key":"10.1016\/j.pharmthera.2009.01.003_bib199","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0014-2999(01)01303-6","article-title":"Pathobiology of neuropathic pain","volume":"429","author":"Zimmermann","year":"2001","journal-title":"Eur J Pharmacol"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725809000138?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725809000138?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,10]],"date-time":"2024-03-10T06:09:42Z","timestamp":1710050982000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725809000138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":200,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["S0163725809000138"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2009.01.003","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2009,4]]}}}